Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens

Selumetinib (ARRY‐142886), an oral, potent and highly selective allosteric mitogen‐activated protein kinase kinase 1/2 inhibitor, is approved by the US Food and Drug Administration for the treatment of pediatric patients aged ≥2 years with neurofibromatosis type 1 with symptomatic, inoperable plexif...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen‐Rabbie, Sarit, Zhou, Li, Vishwanathan, Karthick, Wild, Martin, Xu, Sherrie, Freshwater, Tomoko, Jain, Lokesh, Schalkwijk, Stein, Tomkinson, Helen, Zhou, Diansong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Pediatric Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290801/
https://www.ncbi.nlm.nih.gov/pubmed/34196005
http://dx.doi.org/10.1002/jcph.1935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290801/
https://www.ncbi.nlm.nih.gov/pubmed/34196005
http://dx.doi.org/10.1002/jcph.1935

Ejemplares similares